Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Aequus Pharmaceuticals (AQSZF)

Add AQSZF Price Alert      Hide Sticky   Hide Intro
Search This Board: 
Last Post: 11/17/2017 9:46:49 AM - Followers: 12 - Board type: Free - Posts Today: 0


Update April 8, 2017
Aequus Pharma (AQS.V) (AQSZF)

Market-Cap: c$17 Million (US$12 Million)
Cash: c$5.1 Million << enough untill mid 2018
Price: $0.17

Shares out: 71 Million

>>>>>>NEW interview with Ceo // May, 2017<<<<<<,1770,OnDemand/?v=297513

MUST WATCH to realize the mega potential here

Lots of new Product in-licensing on the way to drive this unknown gem to profitability quickly ( see chart below ):

AQSZF (MC US$ 15M) 2 Marketed Drugs + 3 close to Approval including a Potential Blockbuster = SUPER LIFETIME OPPORTUNITY -

This undiscovered low float rocket is definitely the cheapest Biotech Gem you can get at this time. This Stock has 10 bagger Potential easily with all the Big Drugs close to Market entry .Get some of this Goldmine before she gets discovered .Management alone holding over 16 Million shares Ceo bought 840k shares at 0.30 just a few days ago .GLTA

Presentation November 2016


AQS1301 topline results in 1Q

File for CDN approval of Topiramate XR in 1H 2017

File for CDN approval of Oxcarbazepine XR in 1H 2017

Additional Product acquisitions in 2017

Partnership for AQS1301 in 2017

Operational profitability estimated in 2017

Two products launches to date (Tacrolimus IR and Vistitan™)

3 long-acting, transdermal programs in development, on track to file NDA in 2018

Marketed Products:

Tacrolimus IR : Aequus initiated promotional efforts for tacrolimus IR in December, 2015 •Tacrolimus products currently account for ~30% of a $300 million immunosuppressive market in Canada •Aequus is promoting the first to market generic version of Prograf (tacrolimus IR)

Vistitan : Aequus initiated commercial activities in Q2 2016 for Vistitan (bimatoprost 0.03%) •The Canadian glaucoma market in 2014 was estimated to be over $137 million, of which prostaglandins remain one of the primary treatment options.

NDA Filing for AQS-1301:Expected 3Q2017 Expected Commercial License (If Bioequivalence demonstrated in Phase I, Registration Study may NOT be required for Approval of AQS1301)

AQS-1301, a transdermal aripiprazole product candidate in development for potential weekly use in the treatment of irritability associated with autistic disorder, bipolar I disorder, schizophrenia and major depressive disorder. The currently available dosage forms of aripiprazole (sold primarily under the trade name Abilify®) reached total worldwide sales of over $8 billion USD in 2014. A once-weekly transdermal patch has the potential to improve medication adherence and reduce the frequency of relapse.

Podcast: Aequus Pharmaceuticals CEO Doug Janzen on the low cost of drug commercialization in Canada

James West: Sure. Have you built a pharmaceutical company before, Doug?

Doug Janzen: I have. So I’ve been in this industry for 20 years. I was a banker, then I ran a therapeutic company called Cardiome Pharma; I built that from 50 million to over 1 billion at its peak, and exited after doing an $800 million license with Merck — still the largest license transaction in Canadian history.

James West: Sure. Let me ask that another way: how do you plan to get to – I mean, how many of these deals can you do a year?

Doug Janzen: We bought our commercial infrastructure last July, and since then we’ve launched two products and we’ve just licensed the two Supernus programs. Those four products, we think an aggregate can do $40 million, $45 million at peak sales.

Interactive Brokers Advertisement
Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#176   Sell some product , willya ??? molee 11/17/17 09:46:49 AM
#175   Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole molee 11/16/17 10:18:28 AM
#174   Aequus Granted Chinese Patent for Once-Weekly Transdermal Aripiprazole molee 10/10/17 09:42:21 AM
#173   Some pre-market strength this morning . molee 09/21/17 09:21:02 AM
#172   Sell the news ?? WTF ? molee 09/08/17 11:49:22 AM
#171   This stock is perfect for LONG INVESTOR'S that Chaka 09/07/17 04:47:53 PM
#170   Aequus Announces Positive Results for Proof of Concept molee 09/07/17 02:35:16 PM
#169   Aequus Provides Second Quarter 2017 Operational Highlights molee 08/30/17 01:44:34 AM
#168   Aequus and Ehave Collaborate on Bioinformatics Platform for molee 08/28/17 11:31:36 AM
#167   Aequus Announces Abbreviated Development Path for Transdermal Aripiprazole[/b molee 08/24/17 10:19:18 AM
#166   SP isn't looking so good lately ... ;-( molee 08/21/17 10:16:17 AM
#165   Does anybody have any info relating to the toddski 08/20/17 09:57:33 PM
#164   Aequus and Scientus Agree to Terms for a molee 08/01/17 11:04:45 AM
#163   Aequus Receives Approval from Health Canada to Initiate molee 07/05/17 09:44:10 AM
#162   Aequus Advances Clinical Development of Transdermal Anti-Nausea Patch molee 06/15/17 09:53:18 AM
#161   Santen and Aequus Enter Into a Commercial Collaboration molee 06/13/17 09:21:09 AM
#160   Halted this morning .. Not sure why yet ... molee 06/13/17 09:12:37 AM
#159   I am finally out here , this stock Newlife2017 06/05/17 12:04:45 PM
#158   Aequus Pharmaceuticals and CDRD Announce Research Collaboration to molee 06/01/17 09:29:22 AM
#157   It looks good but it must take off Newlife2017 06/01/17 08:54:31 AM
#156   AQSZF 1st QTR is out : Looks good ... molee 06/01/17 07:47:39 AM
#155   Aequus Provides First Quarter 2017 Financial Highlights molee 05/30/17 01:17:59 PM
#154   Hope is good ! Waiting on news ! Newlife2017 05/30/17 08:55:02 AM
#153   Quarterly report due out today : molee 05/30/17 08:12:54 AM
#152   Very quiet everybody here ! Ummm! What's going Newlife2017 05/21/17 10:09:10 AM
#151   Pure fluff being released by the company. I ronpopeil 05/15/17 03:04:22 PM
#150   Aequus Validates Need for Improved Delivery Methods of molee 05/15/17 02:51:14 PM
#149   Ok ok guys, you guys won! I am Newlife2017 05/11/17 11:32:59 AM
#148   I say this heavily underpriced stock could run BioSpecialist 05/11/17 10:40:45 AM
#147   As many times as I want to, it Newlife2017 05/11/17 08:36:45 AM
#146   How many times are you going to keep ronpopeil 05/11/17 08:32:02 AM
#145   Going nowhere here! Maybe 2018 Newlife2017 05/11/17 08:21:13 AM
#144   Some nice movement today ... @ .20 + molee 05/09/17 10:13:57 AM
#143   I agree with you Todsski, maybe in a Newlife2017 05/08/17 01:44:23 PM
#142   Still not a buy until way closer to toddski 05/08/17 01:27:01 PM
#141   Ceo bought another 95000 shares holding now over BioSpecialist 05/08/17 10:38:18 AM
#140   Too late , am in with 10000 shares Newlife2017 05/05/17 11:10:30 AM
#139   then you should avoid this stock and move BioSpecialist 05/05/17 11:03:01 AM
#138   It keeps going the wrong direction, profits may Newlife2017 05/05/17 09:57:47 AM
#137   It keeps going the wrong Newlife2017 05/05/17 09:56:32 AM
#136   actually i'll take that back . 2016 mspacey4415 05/03/17 06:02:58 PM
#135   thats the problem. stuff like tacrolimus been mspacey4415 05/03/17 05:49:22 PM
#134   NEW Interview out BioSpecialist 05/03/17 12:22:50 PM
#133   Guys once again and I do respect your Newlife2017 05/03/17 09:27:55 AM
#132   So , the funding was at a bought molee 05/03/17 09:20:44 AM
#131   Thats your opinion and i respect it but BioSpecialist 05/03/17 09:14:39 AM
#130   I've been listening this story since last year, Newlife2017 05/03/17 08:39:57 AM
#129   you forget that they are very close to BioSpecialist 05/03/17 08:07:34 AM
#128   Oh yeah , I forgot this was mainly molee 05/03/17 01:24:18 AM
#127   Long term investment on the way! Nothing will Newlife2017 05/02/17 10:27:59 PM